Table 1.
Clinical Characteristics of the study groups
| HCV mono-infected | HIV/HCV co-infected | |
|---|---|---|
| N = 84 | N = 57 | |
| Age, median (range) | 48 (21-79) | 42 (23-58) |
| Male, n | 54 | 49 |
| HCV genotypes | ||
| 1, n (%) | 59 (70%) | 47 (82%) |
| non-1, n (%) | 25 (30%) | 10 (18%) |
| Risk factor for HCV or HIV/HCV infection | ||
| i.v. drug abuse, n (%) | 45 (54%) | 32 (56%) |
| Blood products, n (%) | 0 | 25 (44%) |
| unknown, n (%) | 39 (46%) | 0 |
| HAART | ||
| No, n (%) | n.a. | 10 (18%) |
| Yes, n (%) | n.a. | 47 (82%) |
| PI-based HAART, n (%) | n.a. | 39 (84%) |
| CD4 count, median (range) | n.d. | 430 (10-1486) |
| CD4 < 200/μl, n (%) | n.d. | 8 (14%) |
| AST (U/l), mean ± SD | 59.7 ± 42.4 | 66.6 ± 60.1 |
| ALT (U/l), mean ± SD | 76.3 ± 48.8 | 94.4 ± 84.3 |
| GGT (U/l), mean ± SD | 104.0 ± 128.0 | 128.0 ± 129.0 |
| Bilirubin (mg/dl), mean ± SD | 0.7 ± 0.5 | 1.0 ± 1.0* |
| Platelets (T/l), mean ± SD | 198.3 ± 81.0 | 155.9 ± 68.4* |
| APRI-score†, mean ± SD | 1.5 ± 2.3 | 2.7 ± 5.3 |
| Metavir-Score according to transient elastography (% of patients)° | ||
| F0/1 | 42 (50%) | 31 (54%) |
| F2 | 10 (12%) | 5 (9%) |
| F3 | 11 (13%) | 8 (14%) |
| F4 | 21 (25%) | 13 (23%) |
* p < 0.05, † APRI = AST to platelet ratio. calculation of APRI-score: AST/Platelet count